The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Tysabri continue to outweigh its risks, but has recommended that a number of measures be put in place to manage the risk of the brain infection progressive multifocal leukoencephalopathy (PML) and to make sure that patients and doctors are aware of this risk.

For more information please download: Questions and answers on the review of Tysabri (natalizumab)